{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:33Z","timestamp":1786986873928,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1016\/j.clinthera.2005.01.008","type":"journal-article","created":{"date-parts":[[2005,3,11]],"date-time":"2005-03-11T11:20:28Z","timestamp":1110540028000},"page":"100-110","source":"Crossref","is-referenced-by-count":26,"title":["The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden"],"prefix":"10.1016","volume":"27","author":[{"given":"Peter","family":"Lindgren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Stenestrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klas","family":"Malmberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2005.01.008_bib1","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2005.01.008_bib2","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1365-2796.2004.01324.x","article-title":"Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: A longterm model based on the CURE trial","volume":"255","author":"Lindgren","year":"2004","journal-title":"J Intern Med"},{"key":"10.1016\/j.clinthera.2005.01.008_bib3","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/00149831-200412000-00003","article-title":"The costeffectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study","volume":"11","author":"Lamy","year":"2004","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"10.1016\/j.clinthera.2005.01.008_bib4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: ThePCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2005.01.008_bib5","series-title":"Poster presented at: 52nd Scientific Session of the American College of Cardiology","article-title":"Incremental cost-effectiveness of early and long-term clopidogrel in patients undergoing percutaneous coronary intervention in the CURE trial: The PCI-CURE economic analysis","author":"Mehta","year":"2003"},{"key":"10.1016\/j.clinthera.2005.01.008_bib6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/0272989X9701700205","article-title":"Primer on medical decision analysis: Part 5-Working with Markov processes","volume":"17","author":"Naimark","year":"1997","journal-title":"Med Decis Making"},{"key":"10.1016\/j.clinthera.2005.01.008_bib7","first-page":"59","article-title":"Markov modeling, analysis and microstimulation with the health care module","year":"2004"},{"key":"10.1016\/j.clinthera.2005.01.008_bib8","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0272989X9301300409","article-title":"Markov models in medical decision making: A practical guide","volume":"13","author":"Sonnenberg","year":"1993","journal-title":"Med Decis Making"},{"key":"10.1016\/j.clinthera.2005.01.008_bib9","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/0272989X0002000308","article-title":"Representing both first- and second-order uncertainties by Monte Carlo simulation for groups of patients","volume":"20","author":"Halpern","year":"2000","journal-title":"Med Decis Making"},{"key":"10.1016\/j.clinthera.2005.01.008_bib10","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/1099-1050(200010)9:7<623::AID-HEC539>3.0.CO;2-V","article-title":"Definition, interpretation and calculation of cost-effectiveness acceptability curves","volume":"9","author":"Lothgren","year":"2000","journal-title":"Health Econ"},{"key":"10.1016\/j.clinthera.2005.01.008_bib12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2796.1999.00546.x","article-title":"Costs of coronary heart disease and stroke: The case of Sweden","volume":"246","author":"Zethraeus","year":"1999","journal-title":"J Intern Med"},{"key":"10.1016\/j.clinthera.2005.01.008_bib13","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1053\/euhj.2000.2484","article-title":"At what coronary risk level is it costeffective to initiate cholesterol lowering drug treatment in primary prevention?","volume":"22","author":"Johannesson","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2005.01.008_bib14","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/S0140-6736(01)06350-4","article-title":"Economics of drug treatment: For which patients is it cost-effective to lower cholesterol?","volume":"358","author":"Jonsson","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2005.01.008_bib15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0167-6296(96)00507-3","article-title":"Accounting for future costs in medical costeffectiveness analysis","volume":"16","author":"Meltzer","year":"1997","journal-title":"J Health Econ"},{"key":"10.1016\/j.clinthera.2005.01.008_bib16","series-title":"Two Essays in Health Economics: Consumption and Production by Age, with Emphasis on Health Care Expenditures and Economic Evaluation ofBeta-Blocker Therapy in Heart Failure","author":"Ekman","year":"2001"},{"key":"10.1016\/j.clinthera.2005.01.008_bib18","author":"The Bank of Sweden"},{"key":"10.1016\/j.clinthera.2005.01.008_bib19","series-title":"General Guidelines for Economic Evaluations from the Pharmaceutical Benefits Board","year":"2003"},{"key":"10.1016\/j.clinthera.2005.01.008_bib20","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/hec.903","article-title":"Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions","volume":"13","author":"Fenwick","year":"2004","journal-title":"Health Econ"},{"key":"10.1016\/j.clinthera.2005.01.008_bib21","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(03)12655-4","article-title":"Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: A global and regional analysis on re duction of cardiovascular disease risk","volume":"361","author":"Murray","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2005.01.008_bib22","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/01.CIR.101.4.366","article-title":"Cost-effectiveness of platelet glycoprotein IIb\/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes","volume":"101","author":"Mark","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2005.01.008_bib23","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1056\/NEJM199701303360503","article-title":"Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease","volume":"336","author":"Johannesson","year":"1997","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2005.01.008_bib24","doi-asserted-by":"crossref","first-page":"A296","DOI":"10.1016\/S0735-1097(04)91255-7","article-title":"Long-term costeffectiveness of clopidogrel in pa tients having percutaneous coronary intervention early after acute coronary syndrome: Results fromPCI-CURE","volume":"43","author":"Weintraub","year":"2004","journal-title":"J Am Coll Cardiol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291805000093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291805000093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T01:23:32Z","timestamp":1548638612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291805000093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S0149291805000093"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2005.01.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}